- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| Fr | Medtronic snags FDA approval for body-sensing, closed-loop spinal cord stimulator | ||
| Fr | Labcorp picks up Invitae portfolio for $239M in bankruptcy sale | ||
| Fr | Bristol Myers Squibb closes immuno-oncology, cell therapy-focused Redwood City site | ||
| Fr | Gilead gives up on $4.9B antibody as solid tumor plan unravels | ||
| Do | UW's Baker Lab researchers make AI strides in drug-like peptides | ||
| Do | Boston Scientific sees 70% electrophysiology growth after Farapulse pulsed-field ablation launch | ||
| Do | Under new leadership, BioMarin axes 4 candidates and centers on 3 assets | ||
| Do | Regeneron signs Mammoth gene editing deal worth $100M upfront | ||
| Do | Bristol Myers cutting $1.5B in costs in less than 2 years, with 2,200 employees impacted in 2024 | ||
| Do | Destiny calls time on SporeGen COVID collab, while Santhera hands lonodelestat back to Spexis | ||
| Do | AstraZeneca drops GOLDILOX and the porcupine in R&D update | ||
| Do | Sanofi crosses Sjögren's off $5B drug's hit list after phase 2 data disappoint | ||
| Mi | Cidara regains rights to flu med after Janssen makes good on promise to divest | ||
| Mi | To be better at neuroscience, Biogen will invest outside the therapeutic area | ||
| Mi | New AI drug discovery powerhouse Xaira rises with $1B in funding | ||
| Mi | Roche's pipeline rethink hits 20% of new molecules as cancer candidates join discard pile | ||
| Di | Profluent combines LLMs and CRISPR for open-source gene editing project | ||
| Di | Alpine's data room was the most exclusive club in biotech. Then Vertex became the VIP | ||
| Di | Alcanza buys FDI Clinical Research, adding Puerto Rico sites to trial network | ||
| Di | FDA elevates Medtronic recall of SonarMed safety sensors for NICU ventilators | ||
| Di | Neurocrine-Takeda med reduces depression severity in phase 2, though analysts ask for more data detail | ||
| Di | Incyte, fresh off gaining MorphoSys drug, buys Escient for $750M | ||
| Di | BenevolentAI lays off 30% of staff, exits US site as funding gap looms | ||
| Di | Pop a daily aspirin to prevent colorectal tumors? New research strengthens case | ||
| Di | Sanofi pulls off phase 3 LUNA landing, sparking race to regulators for BTK inhibitor |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
